Role of Peroxisome Proliferator-Activated Receptor alpha in Diabetic Nephropathy.
10.4093/dmj.2011.35.4.327
- Author:
Sungjin CHUNG
1
;
Cheol Whee PARK
Author Information
1. Division of Nephrology, Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea. cheolwhee@hanmail.net
- Publication Type:Review
- Keywords:
Diabetes mellitus;
Kidney;
PPAR alpha
- MeSH:
Aldosterone;
Blood Pressure;
Diabetes Mellitus;
Diabetic Nephropathies;
Dyslipidemias;
Glucose;
Homeostasis;
Inflammation;
Insulin Resistance;
Kidney;
Metabolic Networks and Pathways;
Oxidative Stress;
Peroxisomes;
PPAR alpha
- From:Diabetes & Metabolism Journal
2011;35(4):327-336
- CountryRepublic of Korea
- Language:English
-
Abstract:
With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARalpha expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARalpha likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARalpha may become an important therapeutic target for treating diabetic renal complications.
